May 4, 2005 — The U.S. Food and Drug Administration approved in February revisions to safety labeling to advise that use of alosetron HCl has been associated rarely with serious gastrointestinal tract ...

“Yes, indeed,” Walsh concluded. The committee endorsed the approval of Cancidas for treating patients with aspergillus who had not responded to other drugs. On Jan. 26, 2001, the FDA approved Merck’s ...

Cancidas (caspofungin acetate), given once daily, was evaluated as a treatment for patients three months to 17 years of age with documented or suspected fungal infections. The use of Cancidas in ...

The FDA has approved Cancidas (caspofungin acetate, from Merck) for the treatment of children 3 months to 17 years of age with indicated fungal infections. Indicated fungal infections include: ...

Merck's Cancidas indications expanded with US FDA nod Cancidas was first approved in 2001 for the treatment of invasive aspergillosis in patients who do not respond to or cannot tolerate other ...

Oct. 14, 2004 — The U.S. Food and Drug Administration (FDA) has approved caspofungin acetate for the empiric treatment of presumed fungal infections in the setting of febrile neutropenia, etanercept ...

SAN DIEGO -- CANCIDAS® (caspofungin acetate), given once daily, was evaluated as a treatment for patients three months to 17 years of age with documented or suspected fungal infections. The use of ...

WASHINGTON, Dec 4 (Reuters) - U.S. Food and Drug Administration staff reported on Friday they will recommend labeling changes for Merck's Cancidas (caspofungin) to warn of possible problems related to ...

Merck & Co. won a judge’s ruling that could help it block Novartis AG’s Sandoz unit from selling a generic copy of its Cancidas antifungal treatment until a patent expires in 2017. U.S. District Judge ...

WASHINGTON, Dec 4 (Reuters) - U.S. Food and Drug Administration staff said on Friday that it would recommend labeling changes for Merck's Cancidas to warn of possible liver problems in children taking ...